Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Historical Holders from Q4 2021 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
XLO on Nasdaq
Shares outstanding
53,514,204
Price per share
$0.8427
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
22,051,916
Holdings value
$18,613,906
% of all portfolios
0%
Share change
-1,743,347
Value change
-$1,227,318
Average buys %
+0%
Average sells %
-0%
Number of holders
36
Price from insider filings
$0.6432
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 20% 0% $7,748,179 +$1,101,200 10,613,944 +17% GILEAD SCIENCES, INC. 30 Jun 2025
Frazier Life Sciences Public Fund, L.P. 9.9% 0% $5,942,942 +$1,747,492 8,141,017 +42% Frazier Life Sciences Public Fund, L.P. 30 Jun 2025
Point72 Asset Management, L.P. 9.9% +39% $6,743,200 +$3,371,600 8,000,000 +100% Point72 Asset Management, L.P. 30 Sep 2025
Coastlands Capital LP 10% $3,742,248 5,346,069 Coastlands Capital LP 04 Dec 2025
AbbVie Inc. 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025
STEMPOINT CAPITAL LP 7.2% $3,371,600 4,000,000 StemPoint Capital LP 30 Sep 2025
As of 30 Sep 2025, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 36 institutional shareholders filing 13F forms. They hold 22,051,916 shares of 53,514,204 outstanding shares (41%) .

Top 25 institutional shareholders own 41% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 17% 9,105,451 0% 0.43% $7,673,164
Bain Capital Life Sciences Investors, LLC 8.5% 4,566,817 0% 0.26% $3,848,457
Merck & Co., Inc. 2.8% 1,483,758 0% 0.55% $1,250,363
TAKEDA PHARMACEUTICAL CO LTD 2.8% 1,475,121 0% 7.6% $1,243,084
VANGUARD GROUP INC 2.3% 1,255,692 +9.1% 0% $1,058,549
MORGAN STANLEY 1.8% 961,917 -33% 0% $810,607
AJU IB Investment Co., Ltd. 1.2% 667,742 0% 0.52% $595,559
FMR LLC 0.96% 511,820 0% 0% $431,311
GEODE CAPITAL MANAGEMENT, LLC 0.61% 328,972 -11% 0% $277,257
Squarepoint Ops LLC 0.61% 328,794 +40% 0% $277,075
Trustees of Columbia University in the City of New York 0.47% 249,635 0% 0.03% $210,442
RENAISSANCE TECHNOLOGIES LLC 0.38% 204,700 +25% 0% $172,501
Balyasny Asset Management L.P. 0.37% 198,859 0% 0% $167,578
STATE STREET CORP 0.31% 163,890 +278% 0% $138,110
TWO SIGMA INVESTMENTS, LP 0.16% 87,790 +13% 0% $73,981
XTX Topco Ltd 0.14% 76,045 +119% 0% $64,083
NORTHERN TRUST CORP 0.12% 66,609 0% 0% $56,131
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 56,081 0% 0% $47,259
TWO SIGMA SECURITIES, LLC 0.06% 32,130 0% $27,076
LPL Financial LLC 0.06% 31,000 0% 0% $26,124
TWO SIGMA ADVISERS, LP 0.06% 29,689 0% $25,019
Aptus Capital Advisors, LLC 0.05% 25,000 0% 0% $21,068
SevenBridge Financial Group, LLC 0.05% 25,000 0% 0% $19,333
Mariner, LLC 0.05% 25,000 0% 0% $21,068
HRT FINANCIAL LP 0.05% 24,736 0% $20,000

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 22,051,916 $18,613,906 -$1,227,318 $0.8427 36
2025 Q2 23,795,263 $16,179,092 +$854,217 $0.6799 35
2025 Q1 22,528,206 $16,318,555 -$3,181,066 $0.7244 35
2024 Q4 25,814,355 $24,660,128 -$144,644 $0.9550 34
2024 Q3 15,911,945 $12,534,583 +$1,128,156 $0.7877 32
2024 Q2 14,508,823 $13,746,216 +$1,785,264 $0.9475 31
2024 Q1 12,460,895 $13,460,257 -$2,676,053 $1.08 30
2023 Q4 16,426,281 $9,034,716 -$1,543,598 $0.5500 33
2023 Q3 15,860,160 $33,465,952 -$314,935 $2.11 30
2023 Q2 16,002,286 $41,925,598 -$192,245 $2.62 32
2023 Q1 16,072,057 $50,979,505 +$461,644 $3.17 32
2022 Q4 15,926,513 $42,841,966 -$709,927 $2.69 28
2022 Q3 16,606,568 $48,328,000 -$3,750,524 $2.91 28
2022 Q2 17,880,380 $52,211,910 -$3,647,986 $2.92 29
2022 Q1 18,775,939 $132,746,000 -$2,569,332 $7.07 41
2021 Q4 18,324,586 $269,421,063 +$225,248,000 $16.00 41